Biotechnology company developing oligonucleotide-based therapies to treat rare muscle disorders and other serious diseases.
Avidity Biosciences, Inc. is a dynamic biopharmaceutical company specializing in the development of innovative oligonucleotide-based therapies. Founded in 2012 and headquartered in San Diego, California, the company focuses on advancing antibody oligonucleotide conjugates (AOC) designed to address a wide spectrum of serious diseases.
At the forefront of its pipeline, Avidity Biosciences is pioneering groundbreaking treatments. Its lead product candidate, AOC 1001, targets myotonic dystrophy type 1, a rare genetic disorder affecting muscles. Additionally, the company is developing AOC 1044 for Duchenne Muscular Dystrophy and AOC 1020 for facioscapulohumeral muscular dystrophy, both currently in preclinical stages of development.
Beyond its AOC platform, Avidity Biosciences provides Lumizyme therapy for Pompe disease, underscoring its commitment to advancing treatments for rare diseases. This therapy exemplifies the company's dedication to improving patient outcomes through innovative approaches.
Avidity Biosciences collaborates with leading researchers and healthcare professionals to drive forward its cutting-edge therapies. With a strong emphasis on scientific rigor and therapeutic innovation, the company continues to expand its portfolio and explore new avenues to address unmet medical needs worldwide.